Bladder, Bowel and Stoma Handbook

The essential guide to product selection

Filgotinib (Jyseleca)

Galapagos Biotech


Janus kinase inhibitor


Moderate-to-severely active UC in adults up to 74 years, with caution in patients over 75 years.


Do not use for patients with absolute lymphocyte count less than 0.5x109 cells/litre; absolute neutrophil count less than 1x109 cells/litre; haemoglobin less than 8 g/dL; serious infection (active); tuberculosis (active). Avoid in pregnancy or while breastfeeding. Caution in moderate or severe renal impairment; malignancy; predisposition to infection; risk factors for cardiovascular disease and venous thromboembolism; risk of viral reactivation Patients should receive all recommended vaccinations and be evaluated for tuberculosis and viral hepatitis before treatment. Risk of reduced fertility in male patients. | Potential side effects: Dizziness; increased risk of infection; nausea.

Preparations Available

Oral tablet


Dose: 200mg once daily. Discontinue if no response after 22 weeks.

Sizes Available

100mg tablet (30), £863.10; 200mg tablet (30), £863.10


100mg tablet (30), £863.10; 200mg tablet (30), £863.10

More on: Janus kinase inhibitors